Evaxion A/S

Evaxion A/S announced new three-year immune and clinical outcome data for its personalized cancer vaccine, EVX-01, in a Phase 2 trial for advanced melanoma. The data highlights an 89% vaccine target precision and sustained T-cell and clinical responses, with all patients maintaining their response through the third year. These findings supplement previous two-year data showing a 75% Objective Response Rate and reinforce the potential of Evaxion's AI-Immunology™ platform.

Evaxion A/S announced it will present three-year clinical efficacy data for its personalized cancer vaccine candidate, EVX-01, at the ESMO Congress 2026 in October. The data, stemming from a one-year extension of a Phase 2 trial in advanced melanoma patients, will offer insights into potentially enhanced treatment effects, durability of the immune response, and the vaccine's efficacy as a stand-alone therapy. This builds on previously reported two-year data that demonstrated a 75% Objective Response Rate and impressive durability, with 92% of patients still responding.

Evaxion A/S will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine EVX-01 at the European Society for Medical Oncology (ESMO) Congress in October 2026. This data will offer insights into EVX-01's effect as a stand-alone therapy for advanced melanoma patients, potentially showing enhanced treatment effects and durability. Previous two-year data demonstrated a 75% Objective Response Rate and 92% durable response at two years, with no relapses observed.

Evaxion A/S announced new preclinical data for its EVX-V1 cytomegalovirus (CMV) vaccine program, presented at the International Herpesvirus Workshop 2026. The data supports the multi-component concept of EVX-V1, demonstrating the potential of AI-Immunology™ discovered novel T-cell epitopes to improve control of acute infection, latency, and reactivation in CMV-infected mice. EVX-V1 aims to be a broadly protective vaccine, combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens, addressing a significant clinical challenge with no licensed vaccine currently available.

Evaxion A/S presented new data supporting its multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, at the International Herpesvirus Workshop 2026. The data demonstrated that AI-Immunology™ discovered novel T-cell epitopes have the potential to improve control of acute infection, latency, and reactivation in CMV-infected mice. This builds on previous findings showing the vaccine's ability to reduce viral infection and mediate superior viral neutralization, further strengthening the protective potential of EVX-V1.

Evaxion A/S announced it will present new preclinical data for its vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026. This data is crucial for guiding the final antigen selection for a broadly protective cytomegalovirus (CMV) vaccine. EVX-V1 is an AI-driven, multi-component vaccine designed to address CMV, a widespread infection with a significant market size, valued at $474.6 million in 2023 and projected to grow at a 6.6% CAGR.

Evaxion A/S, a clinical-stage TechBio company, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform. This prestigious award serves as a strong external validation of the platform's innovative use of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. This marks the second recognition from the Galien Prix Foundation in less than a year, highlighting the platform's significant scientific development and tangible impact on human health.

Evaxion A/S has been awarded the prestigious 2026 Prix Galien UK Award for Best digital health solution, recognizing its AI-Immunology™ platform. This marks the second time in less than a year that Evaxion has received an award from the Galien Prix Foundation, underscoring the external validation of its AI-Immunology™ platform. The platform leverages artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

Evaxion A/S announced new preclinical data for its off-the-shelf therapeutic vaccine candidate, EVX-04, for acute myeloid leukemia (AML). The data shows successful expression and secretion of EVX-04 in human cells, leading to immune recognition and activation. The vaccine antigens demonstrated the ability to drive specific immune responses and induce targeted cell-killing in preclinical models. Evaxion plans to present these findings at the European Hematology Association (EHA) 2026 Congress.

Evaxion A/S announced new positive preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), developed using its AI-Immunology™ platform. The data demonstrates EVX-04's successful expression and secretion in human cells, enabling immune recognition and activation. It also showed that the vaccine antigens drive specific immune responses and induce targeted cell-killing, highlighting its potential as an effective cancer vaccine. The company is preparing for regulatory filing for clinical testing, and the data will be presented at the European Hematology Association (EHA) 2026 Congress.